Annals of Oncologyannonc.oxfordjournals.org

Contact us for more information:t: +44 (0) 1865 355 190e: jnlsadvertising@oup.comwww.oxfordjournals.org/corporate

Annals of Oncology is the leading oncology journal in Europe. No other journal provides such excellent readership coverage of clinical and experimental researchers and medical oncologists in Europe.

Advertising & Sales ContactsNaomi ReevesAdvertising Sales Managert: +44 (0)1865 355396e: naomi.reeves@oup.com

Caroline BrackenSupplements Development Managert:+44 (0)1865 353794e: caroline.bracken@oup.com

For reprints, ePrints or tailored products: e: corporate.services@oup.comwww.oxfordjournals.org/corporate

2013 Media Kit

Impact Factor: 6.425Ranking: 17/194 Si: Oncology 2011 Journal Citation Reports® (Science Citation Index, ISI)

Target Audience: Oncologists

Frequency: 12Peer Reviewed: Yes Editor-In-Chief: Professor Jan B. Vermorken

Society Affiliation: European Society for Medical Oncology and also affiliated with the Japanese Society of Medical Oncology

Average Monthly Page Views: 322,050Average Monthly Unique IPs: 90,180Average Available Ad Impressions: 544,260**Combined monthly leaderboard and skyscraper positions

No. Of eTOC Subscribers: 4,480

Useful Information

Print Circulation: 6,800Geographic Breakdown: UK 5% - Europe 65% - North America 9% - Rest of World 21%

A

nn

als of On

cology Volum

e 23 No. 7

July 2012

pp

1653–1929

www.annonc.oxfordjournals.orgwww.esmo.orgwww.jsmo.umin.jp

Annals ofOncology

ISSN 0923-7534 (print)ISSN 1569-8041 (online)

Volume 23 No. 7 July 2012

Scan to view this journal on your mobile device

2

1

2013 Schedule

24/1 January 28 November 2012 07 January 2013

24/2 February 08 January 2013 15 February 2013

24/3 March 31 January 2013 11 March 2013

24/4 April 05 March 2013 10 April 2013

24/5 May 03 April 2013 10 May 2013

24/6 June 03 May 2013 10 June 2013

24/7 July 05 June 2013 10 July 2013

24/8 August 04 July 2013 07 August 2013

24/9 September 05 August 2013 11 September 2013

24/10 October 05 September 2013  09 October 2013

24/11 November 04 October 2013 12 November 2013

24/12 December 05 November 2013 09 December 2013

Volume Issue

Cover Month

Ad artworkdue

Mailout Date

Bonus Conference Distribution

Contact us for more information:t: +44 (0) 1865 355 190e: jnlsadvertising@oup.comwww.oxfordjournals.org/corporate

Print Advertising Options & Rates

Colour1 insertion

3 insertions

6 insertions

12 insertions

Full Page £ 2554 2490 2426 2299

€ 3831 3736 3639 3448

$ 4959 4835 4711 4463

½ Page £ 1536 1498 1459 1382

€ 2304 2247 2189 2074

$ 2983 2908 2833 2684

¼ Page £ 935 911 888 841

€ 1402 1367 1332 1262

$ 1815 1770 1725 1634

Outside Back Cover - 15% extra

Inside Front Cover - 15% extra

Inside Back Cover - 10% extra

Facing Contents 10% extra

Facing Leading Article 10% extra

Special Position Premiums

ASCO 1 - 3 June Chicago

ECCO/ESMO 27 September - 1 October Amsterdam

Contact us for more information:t: +44 (0) 1865 355 190e: jnlsadvertising@oup.comwww.oxfordjournals.org/corporate

Black & White 1 insertion

3 insertions

6 insertions

12 insertions

Full Page £ 1385 1351 1316 1247

€ 2009 1959 1908 1808

$ 2690 2623 2556 2421

½ Page £ 865 843 822 778

€ 1254 1223 1192 1129

$ 1680 1638 1596 1512

¼ Page £ 599 584 569 539

€ 868 846 825 781

$ 1163 1134 1104 1046

Double Page Spread = 2 x Full page rate

More options and solutions in partnership with Annals of Oncology

Loose and Bound Inserts available

Belly Band Sponsored supplements published and distributed with the journal

Article reprints and ePrints useful as conference handouts

A

nn

als of On

cology Volum

e 23 No. 7

July 2012

pp

1653–1929

www.annonc.oxfordjournals.orgwww.esmo.orgwww.jsmo.umin.jp

Annals ofOncology

ISSN 0923-7534 (print)ISSN 1569-8041 (online)

Volume 23 No. 7 July 2012

Scan to view this journal on your mobile device

2

1

A

nn

als of On

cology Volum

e 23 Sup

plem

ent 2 IMPA

KT B

reast Cancer C

onference 3–5 May 2012 B

russels, Belgium www.annonc.oxfordjournals.org

www.esmo.orgwww.jsmo.umin.jp

Annals ofOncology

ISSN 0923-7534 (print)ISSN 1569-8041 (online)

Volume 23 Supplement 2 2012

IMPAKT Breast Cancer Conference

3-5 May 2012Brussels, Belgium

Guest EditorsIMPAKT 2012

Scientific Committee

Scan to view this journal on your mobile device

2

1

This supplement is embargoed until 12:30 Central European Time on 3 May 2012

Pertuzumab: new hope for patients with HER2-positivebreast cancerM. Capelan1,2, L. Pugliano1,3, E. De Azambuja1,2, I. Bozovic1,2, K. S. Saini1,3, C. Sotiriou1,4,S. Loi3,4 & M. J. Piccart-Gebhart1,3*1Department of Medicine, Institute Jules Bordet, L’Université Libre de Bruxelles, Brussels; 2BrEAST Data Center, Institute Jules Bordet, l’Université Libre de Bruxelles,Brussels; 3Breast International Group (BIG), Brussels; 4Breast Cancer Translational Research Laboratory (BCTL) JC Heuson, Institut Jules Bordet, Brussels, Belgium

Received 23 February 2012; revised 27 May 2012; accepted 9 July 2012

Background: Human epidermal growth factor receptor 2 (HER2) overexpression is detected in approximately 15% to20% of all breast cancers (BCs). A revolutionary change in the prognosis of this subgroup of patients has occurredsince trastuzumab therapy was introduced into daily clinical practice. However, because trastuzumab resistance iscommon, new molecules with complementary and/or synergistic mechanisms of action have been developed.Pertuzumab is a new anti-HER2 humanized monoclonal antibody that prevents the formation of HER2 dimers.Material and methods: A computer-based literature search was carried out using PubMed (keywords: breastneoplasm, dimerization, HER-2, pertuzumab); data reported at international meetings are included.Results: This paper describes pertuzumab’s mechanism of action, safety, and role in HER2-positive BCs. It alsoexplores the role of pertuzumab as a single agent or combined with trastuzumab by reviewing data from preclinicalresearch to ongoing clinical trials. Recently published trials, particularly the CLEOPATRA study, highlight the efficacy,tolerability, and increase in disease-free survival associated with this novel agent when combined with trastuzumab.Conclusion: The pertuzumab and trastuzumab anti-HER2 dual blockade is likely to represent a substantial advancefor patients with HER2-positive BCs and a new milestone on the way to personalized medicine.Key words: breast neoplasm, dimerization, HER2, pertuzumab

introductionApproximately 15% to 20% of patients with breast cancer (BC)have human epidermal growth factor receptor 2 (HER2)overexpression or amplification, associated with poorerprognosis [1–3]. The humanized monoclonal antibodytrastuzumab, now used in the metastatic and the adjuvantsettings, has changed the approach to treat patients withHER2-positive BC and the prognosis of the disease [4–8].Nevertheless, not all patients benefit from trastuzumab.

Around 15% of women relapse after trastuzumab-basedtherapy, indicating the presence of de novo or acquiredresistance to trastuzumab [9]. This is the basis for explorationinto additional therapeutics [10], including lapatinib, neratinib,afatinib, trastuzumab emtansine (formerly known astrastuzumab-DM1), heat shock protein 90, histone deacetylaseinhibitors, and pertuzumab [11–17].Pertuzumab is a humanized monoclonal antibody that binds

to the extracellular domain II of HER2. Its mechanism ofaction is complementary to trastuzumab, inhibiting ligand-dependent HER2–HER3 dimerization and reducing signaling

via intracellular pathways such as phosphatidylinositol 3-kinase(PI3K/Akt). Pertuzumab has shown antitumor activity in boththe metastatic and the neoadjuvant settings and is now beingtested as adjuvant therapy [18–22]. In this review, we willdiscuss both pertuzumab and trastuzumab and theirmechanisms of action, explore current evidence and potentialbenefits of treatment with these antibodies, and describecompleted and ongoing clinical trials.

methodsA computer-based literature search was carried out usingPubMed. Articles were selected using the key words ‘pertuzumab’,‘breast neoplasm’, and ‘HER2’. Only papers published in Englishbefore May 2012 were reviewed. Published abstracts frominternational meetings and ongoing trials were also included.

background

the HER family receptorsHER2 family receptors consist of four transmembrane tyrosinekinase receptors present on the surface of normal cells:epidermal growth factor receptor (EGFR, also known as HER1, ErbB1), HER2 (HER2/neu or ErbB2), HER3 (ErbB3), and

*Correspondence to: Dr M. Piccart-Gebhart, Medicine Department, Institut JulesBordet, Boulevard de Waterloo 121, 1000 Brussels, Belgium. Tel: +32-2-541-3206;Fax: +32-2-541-3339; E-mail: martine.piccart@bordet.be

review

review Annals of Oncology 0: 1–10, 2012doi:10.1093/annonc/mds328

© The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology.All rights reserved. For permissions, please email: journals.permissions@oup.com.

Annals of Oncology Advance Access published August 29, 2012

at OU

P site access on August 30, 2012

http://annonc.oxfordjournals.org/D

ownloaded from

Incentives

Publisher’s Discount 10% Agency Commission 10%

Online Advertising Options & RatesAdvertise on annonc.oxfordjournals.org

Contact us for more information:t: +44 (0) 1865 355 190e: jnlsadvertising@oup.comwww.oxfordjournals.org/corporate

Type Size (pixels) CPM* Geo-targeted CPM*

Leaderboard 728 x 90 £42/€63/$84 £50/€75/$100Skyscraper 160 x 600 £50/€75/$100 £60/€90/$120

Online rates

*Minimum order 10,000 impressions

Advertise on table of contents alertsReach a highly engaged ‘opted in’ audience of over 4,480 people

£325/€488/$650 per 1000 registrants (min. charge £325/€488/$650)

eTOC Rates & Sizes

SkyscraperLeaderboard

Your ad here

Your ad here

eTOC

Banner: 468 x 60 pixels Skyscraper: 160x600 pixels

Your ad here

Your ad here

Integrate digital advertising with an ad in the print copy of the journal

In-depth online reports available

By country, region, and or therapy area

TRACK RESPONSE

TARGET YOUR AD

MAXIMUM IMPACT

Print Specifications

Contact us for more information:t: +44 (0) 1865 355 190e: jnlsadvertising@oup.comwww.oxfordjournals.org/corporate

Size (depth x width) Bleed Trim Type area

Full Page 285mm x 222mm 279mm x 216mm 255mm x 178mm

Half Page Landscape 120mm x 178mm

Half Page Vertical 255mm x 85mm

Quarter Page 120mm x 85mm

Double Page Spread - Please supply as two separate full page files

@ PDF files should be created using Adobe Acrobat Distiller 4.0 or higher. @ Files should be composite PDFs, not separated. @ All fonts and images should be embedded and subset below 100%. @ All mono and colour ads should have an effective resolution of 300 dpi (minimum).

Colour ads should be supplied as CMYK only (eg no RGB, Lab colour, ICC colour based or Pantone Colour).

@ Monochrome bitmap images (line-art) should have an effective resolution of 1200 dpi. @ Half-tone dot range should be in the range of 3% to 95%. @ Ads set to the type area should be surrounded by a box, and have no registration marks

or catchlines. @ Bleed ads should have crop marks set to the trim size dimensions, and will be trimmed

accordingly. Please allow 3mm bleed on all four sides. @ Any vector-based objects with transparency effect must be rasterized to 600 dpi in the

source file itself, before creating the PDF.

PDF specifications:

For more information on technical specifications, please contact us.

All advertisements are subject to the approval of the Publisher and/or Editor who reserves the right to reject or cancel any advertisement at any time.